stockrow
Friday 6 November 2026
Export RGNX’s income statement to Excel — free account
REGENXBIO Inc.
RGNX Healthcare Biotechnology
REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024.
- Revenue
- −69.2%
- EPS
- +48.0%
- Free cash flow
- +168.1%
Quarter to September 2026, against a year earlier
7.56
0.18
+2.44%
Follow RGNX
Alert me
REGENXBIO Inc. (RGNX) P/E ratio
REGENXBIO Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 45.1× (June 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 11.1× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 13.2× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 45.1×
Ten-year median
0.0×
Current reading's percentile
82
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CAPR Capricor Therapeutics, Inc. compare | n/m |
| INDP Indaptus Therapeutics, Inc. compare | n/m |
| CBIO Crescent Biopharma, Inc. compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| OVID Ovid Therapeutics compare | n/m |
| RGNX REGENXBIO Inc. | n/m |
| MDXG MiMedx Group, Inc compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 15.3× |
| SLBT SL SCIENCE HLDG compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)